Novel technique grades breast cancer to predict its response to chemotherapy

Article

CONTEXT: Duke University researchers have shown that a test assessing functional and morphologic information gathered during contrast-enhanced MRI renders a score that accurately predicts the response of nine of 10 breast cancer cases to neoadjuvant chemotherapy.

RESULTS: T1-weighted imaging was performed in 20 women with locally advanced breast cancer. Principal investigator Oana Craciunescu, Ph.D., an assistant clinical professor of radiation oncology at Duke, studied the characteristics of tumor perfusion, permeability, and morphology/cellularity. Highly vascular tumors with efficient vascular systems carried more tracer and chemotherapy than tumors fed by less efficient vessels. Homogeneous tumors with an even distribution of blood vessels responded best to therapy. Tumors with densely packed cancer cells did not effectively retain the tracer and responded poorly.

Tumors featuring an equatorial ring of blood vessels also tended to resist chemotherapy because of collapsed vessels.

IMAGE: Morphophysiological tumor scores based on a five-point scale were calculated for a responder (top) and a nonresponder (bottom) to chemotherapy performed before surgery. Enhancement curves revealed the tumor's washin (WiP), washout (WoP), and centripetal (CP) and centrifugal (CF) characteristics. WiP measured the mass's vascularity, permeability, and homogeneity. Tumors with an inhomogeneous pattern or ring enhancement were classified as CP. Tumors with a homogeneous pattern were classified as CF. WoP correlated with tumor cellularity.

IMPLICATIONS: Poor responders identified by this technique can be referred directly to surgery, thereby avoiding the discomfort of chemotherapy. The method will be tested at Duke in a larger trial of patients with locally advanced breast cancer.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.